The Hidden Costs of Financial Conflicts of Interest in Medicine

Psychotherapy and Psychosomatics

Volumn 85, Issue 2, 2016, Pages 65-70

  Fava, Giovanni A ^a,b  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b UNIVERSITY AT BUFFALO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANXIETY DISORDER; CENSORSHIP; CLINICAL PRACTICE; CRITICAL THINKING; DRUG INDUSTRY; EVIDENCE BASED MEDICINE; HEALTH CARE COST; HUMAN; MARKETING; MEDICAL EDUCATION; MEDICAL RESEARCH; MEDICINE; META ANALYSIS (TOPIC); PHYSICIAN; PRIORITY JOURNAL; REVIEW; WITHDRAWAL REFLEX; CONFLICT OF INTEREST; ECONOMICS; INTERPERSONAL COMMUNICATION; ORGANIZATION; PUBLIC RELATIONS; PUBLICATION;

CENSORSHIP, RESEARCH; CONFLICT OF INTEREST; CONGRESSES AS TOPIC; DISCLOSURE; EVIDENCE-BASED MEDICINE; INTERPROFESSIONAL RELATIONS; PERIODICALS AS TOPIC;

EID: 84955571535     PISSN: 00333190     EISSN: 14230348     Source Type: Journal    
DOI: 10.1159/000442694     Document Type: Review

References (40)

1. Rosenbaum L: Reconnecting the dots-reinterpreting industry-physicians relations. N Engl J Med 2015; 372: 1860-1864.
2. Rosenbaum L: Understanding bias-The case for careful study. N Engl J Med 2015; 372: 1959-1963.
3. Rosenbaum L: Beyond moral outrage-weighing the trade-offs of COI regulations. N Engl J Med 2015; 372: 2064-2068.
4. Bekelman JE, Li Y, Gross CP: Scope and impact of financial conflicts of interest in biomedical research: A systematic review. JAMA 2006; 295: 429-433.
5. Orlowski JP, Wateska L: The effects of pharmaceutical firm enticements on physician prescribing patterns. Chest 1992; 102: 270-273.
6. Relman AS: Dealing with conflicts of interest. N Engl J Med 1984; 310; 1182-1183.
7. Drazen JM, Curfman GD: Financial associations of authors. N Engl J Med 2002; 346: 1901-1902.
8. Cappola AR, FitzGerald GA: Confluence, not conflict of interest. Name change necessary. JAMA 2015; 314: 1791-1792.
9. Fava GA, Gatti A, Belaise C, Guidi J, Offidani E: Withdrawal symptoms after selective serotonin reuptake inhibitor discontinuation: A systematic review. Psychother Psychosom 2015; 84: 72-81.
10. Chouinard G, Chouinard V-A: New classification of selective serotonin reuptake inhibitor withdrawal. Psychother Psychosom 2015; 84: 63-71.
11. Offidani E, Guidi J, Tomba E, Fava GA: Efficacy and tolerability of benzodiazepines versus antidepressants in anxiety disorders: A systematic review and meta-analysis. Psychother Psychosom 2013; 82: 355-362.
12. Starcevic V, Brakoulias V, Viswasam K, Berle D: Inconsistent portrayal of medication dependence, withdrawal and discontinuation symptoms in treatment guidelines for anxiety disorders. Psychother Psychosom 2015; 84: 379-380.
13. Margolis J: Conflict of interest and conflicting interests; in Beauchamp TL, Bowie NE (eds): Ethical Theory and Business. Englewood Cliffs, Practice-Hall, 1979, pp 361-372.
14. Fava GA: Conflict of interest and special interest groups. The making of a counter culture. Psychother Psychosom 2001; 70: 1-5.
15. Rothman DJ, McDonald WJ, Berkowitz CD, Chimonas SC, DeAngelis CD, Hale RW, Nissen SE, Osborn JE, Scully JH Jr, Thomson GE, Wofsy D: Professional medical associations and their relationships with industry. A proposal for controlling conflict of interest. JAMA 2009; 301: 1367-1372.
16. Kassirer JP: On the Take. How Medicine's Complicity with Big Business Can Endanger Your Health. New York, Oxford University Press, 2005.
17. Abramson J: Overdosed America. New York, Harper, 2005.
18. Whitaker R, Cosgrove L: Psychiatry under the influence. Institutional corruption, social injury, and Prescription for Reform. New York, Palgrave Macmillan, 2015.
19. Chomsky N: Media Control: The Spectacular Achievements of Propaganda. New York, Seven Stories, 1997.
20. Feinstein AR, Horwitz RI: Problems in the 'evidence' of 'evidence-based medicine'. Am J Med 1997; 103: 529-535.
21. Wolfe SM: Selective clinical trial reporting: betraying trial participants, harming patients. BMJ 2015; 350:h2753.
22. Jane-Wit D, Horwitz RI, Concato J: Variation in results from randomized, controlled trials: stochastic or systematic? J Clin Epidemiol 2010; 63: 56-63.
23. Fava GA: Meta-analyses and conflict of interest. CNS Drugs 2012; 26: 93-96.
24. Page MJ, McKenzie JE, Forbes A: Many scenarios exist for selective inclusion and reporting of results in randomized trials and systematic reviews. J Clin Epidemiol 2013; 66: 524-537.
25. Ebrahim S, Bance S, Athalke A, Malachowski C, Ioannidis JPA: Meta-analyses with industry involvement are massively published and report no caveats for antidepressants. J Clin Epidemiol 2015, DOI: 10.1016/j.clinepi. 2015.08.021
26. Fava GA, Guidi J, Rafanelli C, Sonino N: The clinical inadequacy of evidence-based medicine and the need for a conceptual framework based on clinical judgment. Psychother Psychosom 2015; 84: 1-3.
27. Choudhry NK, Stelfox HT, Detsky AS: Relationships between authors of clinical practice guidelines and the pharmaceutical industry. JAMA 2002; 287: 612-617.
28. Glassman PA, Hunter Hayes J, Nakamura T: Pharmacological advertising revenue and physicians organizations: how much is too much? West J Med 1999; 171: 234-235.
29. Fava GA: The independence of medical journals and the deceptive effects of open access. Psychother Psychosom 2014; 83: 1-5.
30. Ross JS: On ghosts and other unwelcome guests. J Gen Intern Med 2015; 30: 1389-1391.
31. Carey B: Head of mental health institute leaving for Google Life Sciences. The New York Times, Sept 15, 2015, p A19.
32. Lee FLF, Chan JM: Professionalism, political orientation, and perceived self-censorship. Issue Stud 2008; 44: 205-238.
33. Jahoda M: Current Concepts of Positive Mental Health. New York, Basic Books, 1958.
34. Krumholz HM: The end of journals. Circ Cardiovasc Qual Outcomes 2015; 8: 533-534.
35. Krimsky S, Rothenberg LS, Stott P, Kyle G: Scientific journals and their authors' financial interests: A pilot study. Psychother Psychosom 1998; 67: 194-201.
36. Wilkes MS: Conflict, what conflict? When trust goes, so does the healing power of physicians. West J Med 2000; 172: 6-8.
37. Richardson WS, Doster LM: Comorbidity and multimorbidity need to be placed in the context of a framework of risk, responsiveness, and vulnerability. J Clin Epidemiol 2014; 67: 244-246.
38. Fava GA: Unmasking special interest groups: The key to addressing conflicts of interest in medicine. Psychother Psychosom 2010; 79: 203-207.
39. Fugh-Berman A, Hogenmiller A: CME stands for commercial medical education: and ACCME still won't address the issue. J Med Ethics 2015, Epub ahead of print.
40. Lieb K, Scheurich A: Contact between doctors and the pharmaceutical industry, their perceptions, and the effects on prescribing habits. PLoS One 2014;9:e110130.